We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry (DREPAMASSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03985501
Recruitment Status : Recruiting
First Posted : June 13, 2019
Last Update Posted : July 28, 2022
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Three methods are actually used in newborn screening for sickle cell disease (SCD) in France: isoelectric focusing, high performance liquid chromatography and capillary electrophoresis. New technologies are currently under development such as Matrix Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS) using the SpOtOn Diagnostics Reagent Kit available in United Kingdom only.

Zentech company (Liège, Belgium) is developing a package for SCD newborn screening using MS/MS technology. The main objective of the present study will be to compare this new technique with the technique actually used in the hospital center of Lille (sub-contractor for SCD newborn screening of Lyon) and the haemoglobin analysis to test its accuracy (sensitivity and specificity).


Condition or disease Intervention/treatment
Sickle Cell Disease Infant, Newborn, Disease Drepanocytosis Other: SCD newborn screening with the MS/MS method from Zentech

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1440 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry
Actual Study Start Date : March 16, 2021
Estimated Primary Completion Date : September 16, 2023
Estimated Study Completion Date : September 16, 2023

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
newborn screening for sickle cell disease
Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
 Other: SCD newborn screening with the MS/MS method from Zentech
The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent agreement between the two techniques [ Time Frame: 6 months ]
    Non-inferiority (difference <1%) in terms of sensitivity and specificity between the results obtained with the MS/MS method and those obtained with the technique currently used at the Lille CHU (sub-contractor for SCD newborn screening of Lyon)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Day to 27 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Infants with SCD newborn screening conducted in the hospital center of Lyon
Criteria

Inclusion Criteria:

  • Infants with SCD newborn screening conducted in the hospital center of Lyon

Exclusion Criteria:

  • Insufficient quantity of sampling
  • Parents' opposition to their newborn's participation in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985501


Contacts
Layout table for location contacts
Contact: Dr Céline RENOUX, MD, PhD 04.27.85.65.94 ext +33 celine.renoux@chu-lyon.fr
Contact: David CHEILLAN, MD, PhD 04 72 12 96 88 ext +33 david.cheillan@chu-lyon.fr

Locations
Layout table for location information
France
Groupement Hospitalier Est - Hospices Civils de Lyon Recruiting
Bron, France, 69677
Contact: Céline RENOUX, MD, PhD    04.27.85.65.94 ext +33    celine.renoux@chu-lyon.fr   
Contact: David CHEILLAN, MD, PhD    04 72 12 96 88 ext +33    david.cheillan@chu-lyon.fr   
Principal Investigator: Céline RENOUX, MD, PhD         
Principal Investigator: PASCAL GAUCHERAND, MD, PhD         
Principal Investigator: Giovannia CANNAS         
Hopital de la Croix Rousse Not yet recruiting
Lyon, France, 69004,
Contact: Fanny ROUMIEU, MD,PhD    04.26.73.25.53 ext +33    fanny.roumieu@chu-lyon.fr   
Principal Investigator: Fanny ROUMIEU, MD,PhD         
Centre Hospitalier Lyon Sud Recruiting
Pierre-Bénite, France, 69495
Contact: François GOLFIER, PU, PH         
Principal Investigator: GAVANIER DEBORAH, MD, PhD         
Sponsors and Collaborators
Hospices Civils de Lyon
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03985501    
Other Study ID Numbers: 69HCL19_0338
2019-A01346-51 ( Other Identifier: ID-RCB )
First Posted: June 13, 2019    Key Record Dates
Last Update Posted: July 28, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Infant, Newborn, Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
 Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn